CSL – Morgans rates the stock as Add

Funded via a combination of a private placement, a shareholder purchase plan and a mixture of cash and debt, CSL will pay -US$11.7bn for Switzerland-based specialty drug company Vifor Pharma.

The broker doesn’t agree the deal suggests the core plasma business is ex-growth, but rather provides a defensible specialty product portfolio with strong market positions and growth opportunities. Add rating is maintained. Target price rises to $334.7 from $324.4.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.


Target price is $334.70.Current Price is $272.68. Difference: $62.02 – (brackets indicate current price is over target). If CSL meets the Morgans target it will return approximately 19% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →